Survey

This month we would like to know...

With the evolution of the medical home and ACO models of healthcare delivery, what do you see as the most essential means by which pharmacy departments can support the success of such models?

a) More active direct patient outreach, education, and consultation.

b) Enhanced provider education and drug info support.

c) Improved ability to deliver more timely and actionable patient-specific drug alerts to PCPs/care managers.

d) Enhanced mechanisms to monitor and improve patient compliance.

e) More advanced analytics to better risk stratify patients for intervention need.

f) More timely and robust reporting to measure pharmacy-specific quality performance metrics.

Digital Edition

Antibacterial use in children associated with increased, dose-dependent CA-MRSA risk

Antibacterial drug use in children is associated with a dose-dependent increased risk of acquiring community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), according to the results of a population-based, case-control study reported online August 1 in the Archives of Pediatrics & Adolescent Medicine. Read full article.

Once-daily rivaroxaban appears to be as good as dose-adjusted warfarin

Once-daily oral rivaroxaban (Xarelto), a direct factor Xa inhibitor, appears to be as good as dose-adjusted warfarin for the prevention of stroke or major embolism in patients with nonvalvular atrial fibrillation, according to a study published online August 10 in the New England Journal of Medicine. Read full article.

US healthcare system among least
cost-effective in reducing mortality

The US healthcare system is one of the least cost-effective in reducing mortality rates; while the United Kingdom is among the most cost-effective, according to a recent study published in the July issue of Journal of the Royal Society of Medicine Short Reports. Read full article.

HRT reanalyses shows favorable
risk-benefit profile with recommended treatment strategies

The risk-benefit ratio is in favor of hormone replacement therapy (HRT) when initiated near menopause, according to new consensus statements issued by The North American Menopause Society, The American Menopause Society, and the International Menopause Society and published in a recent paper in the July issue of Women's Health. Read full article.

FDA approves Adcetris to treat
2 types of lymphoma

FDA has approved brentuximab vedotin (Adcetris, Seattle Genetics) to treat 2 types of lymphoma. Read full article.

FDA-approved cyanide antidote launches

An antidote indicated for the treatment of acute cyanide poisoning judged to be life-threatening has launched. Read full article.

Contact Us

Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.